To date, following successful clinical trials, several small-molecule PHD inhibitors, including roxadustat (FG-4592), daprodustat (GSK1278863), and vadadustat (AKB-6548), are being used clinically for the treatment of anemia in CKD patients [188]. This evidence concerns the gene PDC and chronic kidney disease.